Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

313
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
313
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.1K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.1K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.1K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.1K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

339
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
339
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

512
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
512

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

Serum Activin A Level and 1-Year Mortality in Atrial Septal Defect-Associated Pulmonary Artery Hypertension: A Case-Control Study From the COHARD-PH Registry.

International journal of vascular medicine·2026
Same author

Designing AI tools to advance health equity in resource-constrained low- and middle-income countries.

Digital health·2026
Same author

Activin A-Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Successful single-center experiences of laser crossectomy in zone zero in Endovenous Laser Ablation (EVLA) for chronic venous insufficiency - a case series.

F1000Research·2026
Same author

Application of murine hindlimb deep vein thrombosis model to assess temporal evolution and hemodynamic sequelae of pulmonary embolism.

Biochemical and biophysical research communications·2026

Related Experiment Video

Updated: Dec 8, 2025

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
09:20

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption

Published on: October 4, 2019

5.8K

Endothelin XVI.

Bambang Widyantoro1, Noriaki Emoto2,3

  • 1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Centre Harapan Kita, Jakarta, Indonesia.

Canadian Journal of Physiology and Pharmacology
|September 16, 2020
PubMed
Summary
This summary is machine-generated.

Endothelin research continues to uncover the peptide's potential as a physiological regulator and therapeutic target. This special issue presents novel findings from the Sixteenth International Conference on Endothelin (ET-16).

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

801
Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization
07:45

Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization

Published on: January 23, 2019

8.6K

Related Experiment Videos

Last Updated: Dec 8, 2025

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
09:20

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption

Published on: October 4, 2019

5.8K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

801
Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization
07:45

Harvest of Endothelial Cells from the Balloon Tips of Swan-Ganz Catheters after Right Heart Catheterization

Published on: January 23, 2019

8.6K

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Pharmacology

Background:

  • The discovery of endothelin (ET) over three decades ago initiated extensive research into its physiological roles.
  • Numerous studies have since elucidated endothelin's molecular mechanisms and clinical implications.
  • Endothelin research holds significant promise for therapeutic advancements.

Discussion:

  • This special issue compiles cutting-edge research presented at the Sixteenth International Conference on Endothelin (ET-16).
  • The presented findings cover diverse biomedical fields, highlighting recent breakthroughs in endothelin research.
  • The conference served as a platform for disseminating novel discoveries.

Key Insights:

  • Endothelin (ET) is a crucial peptide regulator with therapeutic potential.
  • Recent discoveries presented at ET-16 offer new insights into endothelin's multifaceted roles.
  • The field continues to evolve, with ongoing work to fully harness endothelin's capabilities.

Outlook:

  • Continued exploration of endothelin's physiological functions and therapeutic applications is anticipated.
  • Further research aims to translate these findings into clinical benefits for patients.
  • The field of endothelin research is poised for sustained growth and innovation.